Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05465174
Title Nivolumab and DAY101 for Treatment of Craniopharyngioma in Children and Young Adults (PNOC029)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Sabine Mueller, MD, PhD
Indications

craniopharyngioma

Therapies

MLN2480 + Nivolumab

MLN2480

Nivolumab

Age Groups: adult | child
Covered Countries USA


No variant requirements are available.